Use of pharmacogenetic analysis at patients with acute coronary syndrome associated with in-stent restenosis
Abstract
We studied the influence of CYP2C19 gene polymorphism on the development of in-stent restenosis after transdermal coronary intervention in patients with acute coronary syndrome. The obtained data have revealed a gene almost in the half of patients with restenosis in coronary artery, it being responsible for the reduction of clopidogrel metabolism.
About the Authors
A. V. Pavlova
SBE RH №2 - Center of emergency medical care
Russian Federation
Russian Federation
Anna Valentinovna Pavlova - post-graduate student on speciality ‘Cardiology’, doctor cardiologist
Yakutsk, 89644175421
E. S. Kylbanova
Medical Institute of North-Eastern Federal University
Russian Federation
Russian Federation
Elena Semenovna Kylbanova – MD, Head of Internal Medicine and General Practice ( Family Medicine ) Faculty of Postgraduate Medical Education
Yakutsk
E. V. Gurieva
SBE RH №2 - Center of emergency medical care
Russian Federation
Russian Federation
Elga Vladimirovna Gurieva - post-graduate student on speciality ‘Cardiology’, doctor cardiologist, SBE RH №2 - Center of emergency medical care
Yakutsk
N. R. Maksimova
Medical institute clinic of North- Eastern Federal University
Russian Federation
Russian Federation
Nadejda Romanovna Maksimova – MD., professor, head of teaching-scientific laboratory ‘Genome medicine’
Yakutsk
A. L. Danilova
Medical institute clinic of North-Eastern Federal University
Russian Federation
Russian Federation
Danilova Anastasiya Lukichna – PhD, Researcher of teaching-scientific laboratory ‘Genome medicine’ of Medi
Yakutsk
V. A. Vasilev
SBE RH №2 - Center of emergency medical care
Russian Federation
Russian Federation
Vitaliy Anatolevich Vasilev – endovascular surgeon
Yakutsk
B. V. Andreev
SBE RH №2 - Center of emergency medical care
Russian Federation
Russian Federation
Boris Vitalievich Andreev - head physician
Yakutsk
References
1. Invasive cardiology and coronary heart disease / Yu.N. Sokolov, M.Yu. Sokolov, L.N. Kostenko [et al.]. – Kyiv: Morion, 2002. – p. 360.
2. Lomonosova A.A. The problem of restenosis after percutaneous intracoronary interventions and prospects of prevention by means of gene therapy effects / A.A. Lomonosova, S. Yu. Grigorova, Yu.I. Afanasiev // Scientific Gazette. Series Medicine. Pharmacy. – 2010. – № 4. – p. 5-10.
3. National guidelines on the diagnosis and treatment of patients with acute myocardial infarction with ST-segment elevation ECG. First Edition 2007// Cardiovascular therapy and prevention. – 2007; 6 (8). Annex 1.
4. Predictors of thrombosis and restenosis of coronary stents / E.A. Fadeeva, E.F. Kotovshchikova, A.A. Efremushkina [et al.] // Health and education in Siberia. – 2014. – №2.
5. Reasons for in-stent restenosis after interventional treatment of patients with acute coronary syndrome with ST segment elevation / V.V. Buza, Yu.A. Karpov, A.N. Samko [et al.] // Cardiology. – 2009. – №1. – p. 9-13.
6. Sulimov V.A. Resistance to antiplatelet drugs (aspirin, clopidogrel) in patients undergoing elective coronary stenting / V.A. Sulimov, E.V. Moroz // Rational pharmacotherapy in cardiology. – 2012. – Vol. 8, №1. – P.23.
7. Sychev D.A. Pharmacogenetic tes-ting: clinical interpretation of the results: recommendations for practitioners / D.A. Sychev // Moscow. – 2013. – p. 86.
8. Percutaneous coronary intervention. Recommendations of the American College of Cardiology, American Heart Association and the Society for Cardiovascular Angiography and Interventions. Edition 2005 // Journal of the American College of Cardiology 2006; 47. -121.
9. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. – 1996; – 348(9038): 1329-1339.
10. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial/ Fox K.A., S.R. Mehta, R. Peters [et al.] // Circulation – 2004; – 110(10):1202-8.
11. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction / S. Matetzky, B. Shenkman, V. Guetta [et al.] // Circulation. – 2004; – 109: 3171 – 3175.
12. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial / S.R. Steinhubl, P.B. Berger, J.T. Mann 3rd [et al.] // JAMA. – 2002; – 288(19):2411-20.
13. High on-treatment platelet reactivity and P2Y12 antagonist in clinical trials / D. Trenk, S.D. Kristensen, W. Hochholzer, F.-J. Neumann // Thromb. Haemost. – 2013. – 109 (2): 1–11.
14. Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning? / Е.К. Iliodromitis, S. Kyrzopoulos, И.А. Paraskevaidis [et al.] // Heart. 2006; – 92(12): 1821–1826.
15. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting / P.A. Gurbel, K.P. Bliden, K.M. Hayes, U.S. Tantry // J Am Coll Cardioll. – 2005/ – 45:1392-6.
16.
Review
For citations:
Pavlova A.V., Kylbanova E.S., Gurieva E.V., Maksimova N.R., Danilova A.L., Vasilev V.A., Andreev B.V. Use of pharmacogenetic analysis at patients with acute coronary syndrome associated with in-stent restenosis. Yakut Medical Journal. 2017;(1):40-43.
Views:
51
Email this article 